more_reports

The Latest Life Sciences Tools & Diagnostics Articles from Streetwise Reports

Clinical AI Use Surges as Revenue Climbs and Doctors Embrace New Tools

  ()
Doximity Inc. (DOCS:NYSE) reported 7% revenue growth as workflow active prescribers increased more than 30% year over year and AI Search queries climbed more than 25% quarter over quarter.
Tags: Life Sciences Tools & DiagnosticsMedical Devices

Doximity AI Tools Fuel Physician Engagement Growth Amid Healthcare Digital Shift

  ()
Doximity reports fiscal Q1 revenue of $156.6 million with strong workflow growth. See how its AI suite and 85% physician reach position the company in expanding digital health markets.
Tags: Life Sciences Tools & DiagnosticsMedical Devices

Cancer Detection Firm Nears FDA Breakthrough Blood-Test Review

  ()
GRAIL Inc. (GRAL:NASDAQ) announces that an FDA committee will meet in September to evaluate the Premarket Approval (PMA) application for the Galleri multi-cancer early detection (MCED) blood test. Read why one financial expert thinks it will gain approval.
Tags: Life Sciences Tools & Diagnostics

GRAIL Galleri Test Heads to FDA Panel for Multi-Cancer Screening Review

  ()
GRAIL Inc. prepares for its Sept. 23 FDA advisory committee meeting on the Galleri MCED test PMA, backed by large clinical studies and growing commercial revenue in the expanding multi-cancer early detection market.
Tags: Life Sciences Tools & Diagnostics

DarioHealth Reports Q2 Revenue, with 62% Gross Margin as AI Platform Expands

  ()
DarioHealth Corp. (DRIO:NASDAQ) reported US$5.2 million in Q2 revenue, a 62% gross margin and US$13.1 million in contracted and late-stage ARR.
Tags: Life Sciences Tools & Diagnostics

AI Chronic Care Platform Adds Fifth Fortune 50 Client, Lifts Margin to 62%

  ()
DarioHealth reported Q2 revenue of $5.2 million with gross margin rising to 62 percent and contracted ARR reaching $13.1 million after signing a fifth Fortune 50 client and expanding provider-backed care.
Tags: Life Sciences Tools & Diagnostics

This AI Healthcare Platform Is Taking Its New York Expansion Through 2029

  ()
Rocket Doctor AI Inc. (AIDR:CSE; AIRDF:OTC; 939:FRA) extended its EngageWell partnership after an initial virtual-care pilot connected more than 400 underserved New Yorkers with physician-led care.
Tags: Healthcare ServicesLife Sciences Tools & DiagnosticsArtificial IntelligenceTechnology

NY Telehealth Extension Advances Rocket Doctor AI Platform

  ()
Rocket Doctor AI extends its New York telehealth engagement through 2029, combining grants and Medicaid to serve underserved patients while scaling its AI platform amid strong digital health market growth.
Tags: Healthcare ServicesLife Sciences Tools & DiagnosticsArtificial IntelligenceTechnology

Biotech's Non-Cytotoxic Copper-Iodine Wound Platform Shows 72-Hour Antimicrobial Persistence in Lab Testing

  ()
As an aging population expands demand in the wound care market, a smaller player is taking on the one of the most established with its "chemistry-on-demand" technology.
Tags: Biotechnology / PharmaceuticalsLife Sciences Tools & Diagnostics

Smith & Nephew Expands Wound Care Portfolio in $22B Market

  ()
Smith & Nephew advances chronic wound solutions as the global market grows to $30.48B by 2030. Learn about new products, revenue trends, and investor considerations.
Tags: Biotechnology / PharmaceuticalsLife Sciences Tools & Diagnostics

Healthcare Platform Clears Major Security Milestone After Independent Audit

  ()
Rocket Doctor AI Inc. (AIDR:CSE; AIRDF:OTC; 939:FRA) said its wholly owned Rocket Doctor platform achieved SOC 2 Type I compliance following an independent third-party audit of its security, privacy, and operational controls.
Tags: Healthcare ServicesLife Sciences Tools & Diagnostics

Digital Health Platform Achieves SOC 2 Milestone in Booming Sector

  ()
Rocket Doctor AI reaches SOC 2 Type I compliance, strengthening its enterprise position as the digital health market expands rapidly with rising AI adoption.
Tags: Healthcare ServicesLife Sciences Tools & Diagnostics

Cleantech Co. Relaunches Pet Brand Under Its Own Control

  ()
BioLargo Inc. (BLGO:OTCQX) unveils plans to reintroduce its enormously popular CupriDyne-based pet odor products to the consumer market. This time, the company says it will own the brand and do it its own way.
Tags: TechnologySpecial SituationsHealthcare ServicesLife Sciences Tools & DiagnosticsCleantech

Pet Odor Market Ignites BioLargo Consumer Comeback

  ()
BioLargo re-enters the booming U.S. pet odor control market with a direct-to-consumer CupriDyne brand, building on proven demand while advancing water treatment and medical technologies for retail investors.
Tags: TechnologySpecial SituationsHealthcare ServicesLife Sciences Tools & DiagnosticsCleantech

AI Engine Delivers Engagement Gains as Recurring Revenue Outlook Climbs

  ()
DarioHealth Corp. (DRIO:NASDAQ) said its DarioIQ platform reflects the ongoing digital health rotation and AI transformation across healthcare, with broader deployment expected to increase recurring revenue from existing customers by 10% to 15%.
Tags: Life Sciences Tools & DiagnosticsHealthcare ServicesTechnologyArtificial Intelligence

DarioHealth AI Platform Targets 10-15% Revenue Growth from Existing Clients

  ()
DarioHealth's DarioIQ AI engine is positioned to lift B2B2C recurring revenue 10-15% from current customers while the AI healthcare market expands rapidly toward hundreds of billions.
Tags: TechnologyHealthcare ServicesLife Sciences Tools & DiagnosticsArtificial Intelligence

Air Force Bases Renew Their Contracts With Cleantech Pioneer

  ()
Cleantech and life sciences innovator BioLargo Inc. (BLGO:OTCQX) says its engineering division has secured contract renewals worth over US$1.4 million. Find out why experts like this technology incubator's structure.
Tags: Life Sciences Tools & DiagnosticsTechnologyBiotechnology / PharmaceuticalsSpecial Situations

First-of-Its-Kind US Brain Imaging Clinic Takes Delivery of Key PET Scanner

  ()
Grey Matters Health Inc. (GREY:CSE; AGW0:FRA; AGNPF:OTCQB) received its first brain-dedicated PET scanning system for its flagship Florida NovaScan Neuroimaging Clinic, which the company said will be the first U.S. facility dedicated to brain-only PET imaging for Alzheimer's disease and other neurological conditions.
Tags: Life Sciences Tools & DiagnosticsHealthcare Services

BioLargo (BLGO) Aligns CEO Pay With Growth as Contracts Renew

  ()
BioLargo Inc. (BLGO) secures $1.4M Air Force contract renewals while advancing PFAS and wound care technologies through key partnerships and aligned leadership incentives.
Tags: Life Sciences Tools & DiagnosticsTechnologyBiotechnology / PharmaceuticalsSpecial Situations

Grey Matters Health Inc. Targets Alzheimer's PET Imaging Opportunity

  ()
Grey Matters Health Inc. advances first U.S. brain-dedicated PET clinic for Alzheimer's detection amid surging diagnostics demand. Learn the key facts for investors.
Tags: Life Sciences Tools & DiagnosticsHealthcare Services

Digital Health Pioneer Targets Massive Breakthrough Chronic Care Market

  ()
AI-driven digital health solutions pioneer DarioHealth Corp. (DRIO:NASDAQ) announces a partnership that it says will give it access to a network spanning all 50 states. Find out why analysts like the direction the company is taking.
Tags: Healthcare ServicesLife Sciences Tools & Diagnostics

DarioHealth (DRIO) Expands Reach via Beluga Health Deal

  ()
DarioHealth (DRIO) integrates its AI platform with Beluga Health's network to scale provider-backed care. Discover growth catalysts, analyst targets, and investor considerations.
Tags: Healthcare ServicesLife Sciences Tools & Diagnostics

Grey Matters Health Inc. Advances US Alzheimer's Clinics

  ()
Grey Matters Health Inc. closes CA$1.25M financing to launch brain-specific PET clinics targeting the expanding Alzheimer's diagnostics market and early detection demand.
Tags: Healthcare ServicesLife Sciences Tools & Diagnostics

Alzheimer's Imaging Push Gains Fresh Funding as U.S. Clinic Plans Move Forward

  ()
Grey Matters Health Inc. (GREY:CSE; AGW0:FRA; AGNPF:OTCQB) closed an expanded US$1.25 million private placement and said proceeds will support its Alzheimer's disease program and planned first U.S. brain-specific neuroimaging clinic.
Tags: Healthcare ServicesLife Sciences Tools & Diagnostics

Sernova Biotherapeutics Advances Toward Diabetes Solutions with FDA Orphan Drug Designation and Strengthened Capital Base

  ()
Sernova Biotherapeutics leverages its Cell Pouch technology and recent FDA orphan drug designation to address type 1 and type 3c diabetes amid a growing global market, supported by improved financial stability for retail investors.
Tags: Regenerative MedicineMedical DevicesLife Sciences Tools & Diagnostics

Showing Results: 1 to 25 of 51 Next